STOCK TITAN

GILD insider sales: 3,000 shares planned; recent disposals total 34,000 shares

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Gilead Sciences (GILD) Form 144 notice records a proposed sale of 3,000 common shares via Morgan Stanley Smith Barney for an aggregate market value of $340,710, with an approximate sale date of 09/15/2025 on NASDAQ. The shares were acquired as performance shares on 01/31/2024. The filing also discloses that Johanna Mercier sold 34,000 shares across three transactions in the past three months (06/16/2025, 07/15/2025, 08/15/2025) generating total gross proceeds of $3,982,524.65. The filer affirms no undisclosed material adverse information and the notice is presented as a live filing.

Positive

  • Clear compliance with Rule 144 including broker, acquisition date, and past three months of sales
  • Securities originated as performance shares, indicating compensation-related provenance rather than a market purchase
  • Filer affirms no undisclosed material adverse information consistent with Form 144 declarations

Negative

  • Insider sold 34,000 shares in the past three months, totaling $3,982,524.65, which may be viewed negatively by some investors
  • Proposed sale adds supply of shares to market, albeit small relative to outstanding shares (1,240,806,916)

Insights

TL;DR: Routine insider sale of performance shares; not material to Gilead's market cap.

The notice documents a small proposed sale of 3,000 shares worth $340,710 and prior insider sales totaling 34,000 shares for $3.98 million. Relative to the reported outstanding share count of 1.2408 billion, these transactions represent de minimis dilution or supply impact. The shares were granted as performance awards, indicating compensation-related disposition rather than an operational red flag. Overall, this is a routine disclosure under Rule 144 reflecting insider liquidity activity rather than company performance.

TL;DR: Compliance appears proper; disclosure of prior monthly sales is transparent and consistent with Rule 144 practice.

The filer identifies acquisition type, acquisition date, capacity of broker, and past three months of sales by the same person, which aligns with Rule 144 reporting expectations. The representation that the seller has no undisclosed material information is standard. The pattern of periodic sales from the same individual suggests scheduled or staged dispositions commonly seen with vested awards. No governance concerns are evident from the notice alone.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filed for GILD indicate?

The Form 144 shows a proposed sale of 3,000 common shares of Gilead Sciences valued at $340,710, with an approximate sale date of 09/15/2025 on NASDAQ.

Who is the seller and what recent sales are disclosed?

The filing references sales by Johanna Mercier, who sold 34,000 shares across 06/16/2025, 07/15/2025, and 08/15/2025 for total gross proceeds of $3,982,524.65.

How were the shares being sold originally acquired?

The 3,000 shares subject to the proposed sale were acquired as performance shares on 01/31/2024 from the issuer.

Does the filing state any undisclosed material information?

By signing the notice the person represents they do not know any material adverse information about the issuer that has not been publicly disclosed.

Through which broker will the shares be sold?

The proposed sale lists Morgan Stanley Smith Barney LLC Executive Financial Services as the broker.
Gilead Sciences Inc

NASDAQ:GILD

GILD Rankings

GILD Latest News

GILD Latest SEC Filings

GILD Stock Data

155.92B
1.24B
0.1%
90.75%
1.42%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States
FOSTER CITY